News

Tesamorelin for Women: Evidence and Menopause

Creator: Julian Reyes, Health Writer
Published: 2026-09-06

Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.

Julian Reyes, Health Writer September 6, 2026 6 min read

A woman in a rust jacket and charcoal trousers walks toward the camera on a quiet desert trail

The short version

Women made up only 14% and 16% of the two pivotal trial populations; one trial reported a similar response by sex but did not publish the female effect size or confidence interval.
No trial has tested tesamorelin specifically for menopause-associated abdominal change, hot flashes, sleep disruption or other menopause symptoms.
In 380 SWAN participants, visceral fat increased at an annualized 6.24% during the menopause transition, but that finding explains the question—it does not establish tesamorelin as menopause treatment.
A 196-woman hormone-therapy trial found oral estradiol lowered IGF-1 while transdermal estradiol did not; it did not test tesamorelin, so no standard interaction adjustment can be inferred.
Pregnancy is contraindicated in branded labeling, and a prescribing review also considers glucose, IGF-1, pituitary history, malignancy history and hormone therapy.

Tesamorelin for women has human evidence, but almost all of it comes from mixed-sex HIV lipodystrophy trials dominated by men. One pivotal study reported a similar visceral-fat response in men and women, but women were only 14% of participants and the paper did not publish a female effect size. There is no trial showing that tesamorelin treats menopause-related abdominal change, overall weight, hot flashes or other menopause symptoms. Pregnancy is a contraindication, and menopausal hormone therapy needs review because estrogen route can change growth-hormone and IGF-1 biology.

What tesamorelin for women actually means

Tesamorelin is an analogue of growth-hormone-releasing hormone. It signals the pituitary to release growth hormone, which in turn raises insulin-like growth factor 1, or IGF-1. It is not estrogen, progesterone or menopause hormone therapy.

That distinction separates a measurable biological response from the outcomes women often ask about. A rise in IGF-1 does not establish improvement in sleep, energy, hot flashes or body weight. What tesamorelin does explains the pathway; the tesamorelin belly-fat evidence covers visceral versus subcutaneous fat and the trial results in detail. The narrower question here is whether those findings can be read as female-specific evidence.

The women who were studied were adults with HIV who met specific abdominal-fat criteria; being female or menopausal was not the indication. A woman seeking care for a midlife body-composition change without HIV-associated lipodystrophy is asking a different clinical question. The mechanism may be the same, but the evidence population is not. Mixed-sex findings can support a clinical discussion, but they cannot answer outcomes the trials never measured.

What the female subgroup shows—and does not show

Women were included in the pivotal program, but they were a small minority. That makes the evidence more useful than an all-male dataset and less precise than a trial designed for women.

Question	What the evidence can say	What remains unknown
Did women participate?	Yes. Men made up 86% of the first phase 3 trial and 84% of the second.	Neither trial was powered around women or menopause status.
Was the response different by sex?	The first trial reported no significant sex-by-treatment interaction and said the visceral-fat change was similar in men and women.	The female effect size and confidence interval were not published; the paper says the data were not shown.
Are the safety rates female-specific?	The program reported pooled adverse-event rates.	It did not publish a robust sex-stratified safety estimate.

The first study randomized 412 adults and included about 14% women. Its full report states that the treatment difference was similar by sex, but does not show the underlying female result (Falutz et al., New England Journal of Medicine, 2007). That supports no detected difference in that trial. It does not support a precise prediction for an individual woman.

Why menopause brings this question up

The menopause transition can change where fat is stored even when the scale does not tell the whole story. In a longitudinal SWAN analysis of 380 women followed for a median 11.8 years, visceral fat began increasing during the transition at an annualized 6.24%; the trajectory slowed after menopause (Greendale et al., Journal of Clinical Endocrinology & Metabolism, 2021).

That explains the interest in tesamorelin, but it does not fill the clinical gap. The tesamorelin trials did not enroll women because they had menopause-associated abdominal change, did not stratify results by peri- or postmenopause, and did not test menopause symptoms. A plausible overlap in fat distribution is not proof of a menopause treatment.

Where a tesamorelin–ipamorelin combination fits

Adding ipamorelin creates a different treatment question. The two compounds signal growth-hormone release through different receptors, but no clinical trial has tested their combination specifically in women or during menopause. The tesamorelin and ipamorelin evidence separates the receptor rationale from the missing combination data. Results from tesamorelin alone cannot be assigned to the pair.

Hormone therapy changes the review, not the evidence

Menopausal hormone therapy is not automatically incompatible with tesamorelin, but the exact medicines and routes matter. In a randomized study of 196 healthy postmenopausal women, oral estradiol plus progesterone lowered IGF-1 compared with placebo and transdermal estradiol; transdermal estradiol did not significantly change IGF-1 versus placebo (Sonnet et al., Clinical Endocrinology, 2007). That study did not administer tesamorelin, so it demonstrates route-dependent biology rather than a tested interaction or a dose-adjustment rule.

The current Egrifta WR label adds a separate medication issue: growth hormone may alter clearance of drugs metabolized through cytochrome P450, including sex steroids. It calls for monitoring potential interactions. A prescriber therefore needs the name, route and amount of every estrogen, progestogen or other hormone in the regimen. There is no evidence-based shortcut such as treating all patches differently from all pills.

Pregnancy and the other screening boundaries

Pregnancy is a clear exclusion. The FDA prescribing information revised in March 2025 contraindicates Egrifta WR during pregnancy because changing pregnancy-associated visceral fat offers no known benefit and animal data indicate potential fetal harm. The label also reports no human milk data for tesamorelin.

Other screening points follow the same growth-hormone pathway: active malignancy, a history affecting the hypothalamic-pituitary axis, glucose intolerance or diabetes, persistent IGF-1 elevation, and interacting medications. Fluid retention, joint symptoms, carpal-tunnel symptoms and injection-site reactions are relevant regardless of sex; tesamorelin side effects covers those trial rates without implying they were measured separately in women.

The approved use and the compounded product are different

As of August 2026, Promise dispenses tesamorelin as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Egrifta WR is not a compounded preparation; it is FDA-approved for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its label says it is weight-neutral and not indicated for weight-loss management.

The FDA explains that compounded drugs do not receive premarket review for safety, effectiveness or quality. Regulatory status is one input into care, not a marketing gate: a licensed provider may still prescribe a compounded formulation when clinically appropriate, and that decision is between the patient and doctor.

What realistic expectations look like

A useful expectation is a defined clinical target, not a general promise about a changing midlife body. Published outcomes were assessed over months and reflect group averages in specific populations. They do not establish predictable scale loss, a visible change in the fat just under the skin, or improvement in menopause symptoms. Female-specific response and safety estimates remain uncertain.

The reviewing provider can decide whether the target matches the evidence, interpret baseline glucose and IGF-1, account for hormone therapy and set a monitoring plan. At Promise, a licensed provider reviews every request and prescribes or declines on medical eligibility; not everyone qualifies.

Common questions

Does tesamorelin work differently in women?

We do not know whether it works differently by sex. A 412-person pivotal trial, in which women were 14% of participants, reported a similar visceral-fat response in men and women and found no significant sex-by-treatment interaction. However, the female result and confidence interval were not published, so the study cannot provide a women-specific effect estimate.

Can tesamorelin help with menopause belly fat?

There is no clinical trial of tesamorelin specifically for menopause-associated abdominal change. Longitudinal research shows visceral fat can increase during the menopause transition, which explains the interest, but the pivotal tesamorelin studies enrolled adults with HIV-associated lipodystrophy and were mostly male. Tesamorelin should not be presented as menopause treatment or predictable cosmetic spot reduction.

Can women use tesamorelin with hormone therapy?

Possibly, but the combination requires an individualized medication review. Oral and transdermal estrogen can affect the growth-hormone–IGF-1 axis differently, and the Egrifta WR label says growth hormone may alter clearance of some sex steroids. No trial has established a standard tesamorelin adjustment for menopausal hormone therapy, so the prescriber needs the exact estrogen, progestogen, route and amount.

Is tesamorelin safe during pregnancy?

No. The Egrifta WR prescribing information contraindicates use during pregnancy because altering pregnancy-associated visceral fat offers no known benefit and animal data indicate potential fetal harm. Pregnancy status is therefore a critical part of screening for any tesamorelin request. The label also says there are no data on tesamorelin in human milk or its effects on a breastfed child.

Is tesamorelin a weight-loss drug for women?

No. The branded label describes Egrifta WR as weight-neutral and says it is not indicated for weight-loss management. Tesamorelin studies measured visceral fat with imaging in selected populations; they do not establish predictable scale loss or reduction of the pinchable subcutaneous layer. A women-specific evaluation should begin with the actual clinical target rather than a general weight-loss expectation.

What should a woman expect from a tesamorelin evaluation?

Expect a review of the intended outcome, pregnancy status, glucose control, IGF-1, pituitary history, malignancy history, hormone therapy and other medications. The provider should also explain that female-specific trial estimates are limited and define how response and tolerability would be monitored over time. The evaluation can result in a prescription, more questions or a clinical decline.